Zone 1 (EU) including Switzerland and United Kingdom: Belgium, Bulgaria, Denmark (except Faroe Islands and Greenland), Estonia, Finland (excluding land Islands), France (except overseas areas and departments), Germany, Greece (except Mount Athos), United Kingdom (except Channel Islands), Ireland, Italy (except Livigno and Campione d'Italia), Croatia, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands (except non-European territories), Austria, Poland, Portugal, Romania, Sweden, Slovakia, Slovenia, Spain (except Canary Islands, Ceuta + Melilla), Czech Republic, Hungary, Cyprus / Republic (except northern part), including Switzerland
PlexusDx works with compounding partners who document their stability testing and provide transparent BUD assignments to patients and providers
However, using a degraded peptide means dosing becomes unpredictable, since you cannot know how much active compound remains
6 (download TIF Unprocessed western blots and/or gels
Verify twice before injecting into the vial
